Chronic Toxicities Related to Treatment in Patients With Localized Cancer

CANTO - Breast Inclusion Criteria: * Women, * Aged 18 years and over, * With an invasive breast cancer diagnosed by cytology or histology, * No clinical evidence of metastasis at the time of inclusion, * Untreated including scored for breast cancer surgery in progress, * Patient receiving a social security system, * Patient mastering the French language, * Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage. * (Since february 2022) Patient : 1. Age \< 45 years at diagnostic 2. Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2- 3. Or Eligible to Pembrozilumab, Olaparib, TDM1, Abemaciclib or Ribociclib Exclusion Criteria: * Metastatic breast cancer, * Local recurrence of breast cancer, * History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix, * Already received treatment for breast cancer ongoing, * Blood transfusion performed for less than six months, * Persons deprived of liberty or under supervision (including guardianship). CANTO - Lung Inclusion Criteria: * Aged 18 years and over, Having lung cancer diagnosed by cytology or histology or suspected cancer of the lung, * Tumor cTX to cT4, cN0-3, * No clinical evidence of metastasis at the time of inclusion (patients with metastases on extension assessment within 6 months following diagnosis will be removed from the study), * Eligible for curative treatment by surgery or radiotherapy \* (note patients treated with exclusive chemotherapy, exclusive radiotherapy or exclusive stereotactic radiotherapy will be out of study) * Lack of treatment received for current lung cancer, including surgical treatment * Patient benefiting from a social protection scheme, * Patient mastering the French language, * Free and informed consent for additional biological samples, the different questionnaires and the collection of information on resource consumption. Exclusion Criteria: * Metastatic lung cancer, * Local relapse of lung cancer, * History of cancer within 3 years prior to study entry other than basal cell cutaneous or epithelioma in situ of the cervix, * Treatment already received for current lung cancer, * Blood transfusion carried out less than 6 months ago, * Persons deprived of liberty or under guardianship (including curatorship).